LSP 2.5g/50 mL: 1500C ¼ . Cost calculated by rounding to the number of vials (for example, 4F-PCC 1600IU=4 vials). Currently, daily hospital stay cost in a surgical unit =258,8C ¼ /day. Results 691 patients included,148(21,0%) anticoagulated. 25 (4,0%) excluded because of no surgery, so the final analysis included 666 patients,141 anticoagulated. 63(44,7%) were anticoagulated with acenocoumarol, 40(28,4%) apixaban, 29 (20,6%) rivaroxaban, 12(8,5%) dabigatran, 8(5,7%) edoxaban and 1(0,7%) with warfarin. Early surgical goal in orthogeriatric patients in Spain (proximal femur fracture in patients >65 years) is intervention in <48 hours since admission. It was only achieved in 12,8% of anticoagulated patients in 2020 and 2021(18). Meantime between admission and surgery =4 ± 6 days. Days between admission and surgery =574 for all anticoagulated patients in total. Estimated total cost of anticoagulant reversal =134.683,5C ¼ (955,2C ¼ /patient). Assuming this strategy is used and surgery is performed in the first 24 hours, hypothetical hospitalisation cost could decrease, saving 574 admission days and 148.537,3C ¼ . Conclusion and RelevanceEarly hip fracture surgery within 48 hours from admission reduces complications in elderly patients. Anticoagulation reversal strategies in anticoagulated patients have a significant economic impact but would allow to reduce hospital stay with potential savings in healthcare costs.

No abstract

closure integrity, impurities, charge variants, oxidation, endotoxin, particulates and biological activity. Results A total of 132 syringes underwent three freeze-thaw cycles, exposing each syringe for a total of 144 hours to 30°C and 144 hours to À5°C. Following exposure, 66 syringes were used for the analysis and 66 were retained. The effects of this thermal cycling on the critical quality attributes of SB5 from baseline is shown in table 1. Conclusion and relevance SB5 was stable in the immediate pack when exposed to multiple freeze-thaw cycles. These results may help hospital pharmacists assess the impact of temperature excursions during shipment or storage on product quality of SB5. REFERENCES AND/OR ACKNOWLEDGEMENTS Conflict of interest Corporate sponsored research or other substantive relationships: HE is an employee of, and holds stock in Biogen, responsible for the commercialisation of SB5. JK, JY, DP, SJH and SJP are employees of Samsung Bioepis, the marketing authorisation holder of SB5.